Saltar al contenido
MilliporeSigma

Saltar a

F3806

Fadrozole hydrochloride

≥98% (HPLC), nonsteroidal aromatase inhibitor, powder

Sinónimos:

4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)-benzonitrile, Afema, CGS 16949A

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas
A ustedes/SKUDisponibilidadPrecio
10 mg

Disponible para enviar HOYdesdeMILWAUKEE

$145.00
50 mg

Disponible para enviar HOYdesdeMILWAUKEE

$576.00
$489.60

Acerca de este artículo

Fórmula empírica (notación de Hill):
C14H13N3·HCl
Número CAS:
Peso molecular:
259.73
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder

$145.00


Disponible para enviar HOYDetalles


Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


Nombre del producto

Fadrozole hydrochloride, ≥98% (HPLC)

Quality Segment

assay

≥98% (HPLC)

form

powder

solubility

DMSO: >20 mg/mL

originator

Novartis

storage temp.

room temp

SMILES string

Cl.N#Cc1ccc(cc1)C2CCCc3cncn23

InChI

1S/C14H13N3.ClH/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14;/h4-7,9-10,14H,1-3H2;1H

InChI key

UKCVAQGKEOJTSR-UHFFFAOYSA-N

Biochem/physiol Actions

Fadrozole is a nonsteroidal aromatase inhibitor.
Fadrozole is a nonsteroidal aromatase inhibitor. Fadrozole is a very potent and highly selective inhibitor of the aromatase enzyme system in vitro and estrogen biosynthesis in vivo. It inhibited the conversion of [4-14C]androstenedione to [4-14C]estrone by human placental microsomes in a competitive manner (Ki = 1.6 nM). At a substrate concentration 3-fold the Km, Fadrozole was 180 times more potent, as an inhibitor, than aminoglutethimide (Cat. No. A9657), exhibiting half-maximal inhibition at 1.7 nM as compared to 0.3 μM. In vivo, Fadrozole lowered ovarian estrogen synthesis by gonadotropin-primed, androstenedione treated, immature rats by 90% at a dose of 260 μg/kg (PO). In vivo, Fadrozole leads to sequelae of estrogen deprivation (e.g. regression of DMBA-induced mammary tumors) without causing adrenal hypertrophy in adult rats. It blocked aromatase by 50% in human breast cancer homogenates, live breast cancer cells, human placental microsomes, and porcine ovarian microsomes at concentrations of 0.008 to 0.02 μM.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 1

Este artículo
PZ0254PZ0037P0099
assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

room temp

storage temp.

room temp

storage temp.

room temp

storage temp.

room temp

solubility

DMSO: >20 mg/mL

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 10 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear (warmed)

originator

Novartis

originator

-

originator

-

originator

Johnson & Johnson


pictograms

Skull and crossbonesHealth hazard

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral - Repr. 2

Clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



Questions

Reviews

No rating value

Active Filters